Shots:

• The P-II PRISM-EXT, OLE of the PRISM3 trial evaluates CP101 vs PBO in 132 patients with recurrent CDI. Patients were enrolled in PRISM3 or directly enrolled after experiencing a CDI recurrence without prior treatment in PRISM3
• In the PRISM-EXT trial, 80.3% of participants achieved sustained clinical cure @8wks. following SoC antibiotics in PRISM-EXT & 78.8% of patients achieved sustained clinical cure @24wks., no treatment-related serious AEs were reported. The safety profile was consistent with that observed in PRISM3
• Finch already started recruitment for its P-III PRISM4 trial of CP101 for the prevention of recurrent CDI with results expected in 2023

  Ref: Finch Therapeutics | Image: Finch